Fig. 4From: PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trialsForest plot of aggregated data representing the risk ratios of grade 3 ≤ adverse events in newly-diagnosed OC. OC-ovarian cancer, PARPi-poly ADP ribose polymerase inhibitor, MDS / AML- myelodysplastic syndrome or acute myeloid leukemia, CI-confidential intervalBack to article page